1456-P: Type 1 Diabetes Care and Device Use in Older Adults—Transatlantic Comparison Based on T1DX-QI and DPV Registries
Authors: FANTASIA KATHRYN , LANZINGER STEFANIE , ROMPICHERLA SAKETH , GRAMMES JENNIFER J. , O'MALLEY GRENYE , MADER JULIA K. , GOLDEN LAUREN , KOPP FLORIAN , MAAHS DAVID M. , JEHLE PETER M. , EBEKOZIEN OSAGIE , HOLL REINHARD W. , COLLABORATIVE T1DX-QI 
Published: June 2024

Continuous glucose monitoring (CGM), insulin pump, and automated insulin delivery (AID) use improve glycemia and quality of life. Device use has increased in recent years. However, rates of device use in older adults are underreported. The aim of this study is to describe sensor, pump, and AID use and glycemic outcomes in adults with type 1 diabetes (T1D) age &lt;u&gt;&gt;&lt;/u&gt;60 years from the Type 1 Diabetes Exchange Quality Improvement Collaborative (T1DX-QI) and the Diabetes Patients Follow-up (DPV) registry.
We report cross-sectional data of adults &gt;&lt;/u&gt; 60 years with T1D seen in 2022 in the T1DX-QI (n=1217) and DPV (n=2042) registries for device use and HbA1c.
Median age was 67.5 years [interquartile range {IQR} 63.4, 72.8] in T1DX-QI and 68.9 [IQR 63.6, 75.7] in DPV. CGM use was similar (50.3%, 47.9%), insulin pump use was approximately 2x higher (40.7% vs 17%), and AID use approximately 3x higher (20.4% vs. 6.4%) in the T1DX-QI as compared to DPV registry (Fig. 1). HbA1c was lower in T1DX-QI (median 7.1% [6.5, 7.8]) than DPV (median 7.4% [6.8, 8.19]).
Device use was lower with increasing age across both registries. Rates of insulin pump and AID use were higher, and median HbA1c was lower, across all age groups among older adults in the T1DX-QI as compared to the DPV registry.

Disclosure
K. Fantasia: None. S. Lanzinger: None. S. Rompicherla: None. J.J. Grammes: Advisory Panel; Novo Nordisk. Other Relationship; Novo Nordisk, Lilly Diabetes. G. O'Malley: Research Support; Dexcom, Inc., Insulet Corporation, Abbott, Tandem Diabetes Care, Inc., MannKind Corporation. J.K. Mader: Advisory Panel; Becton, Dickinson and Company. Speaker's Bureau; Becton, Dickinson and Company, A. Menarini Diagnostics, Boehringer-Ingelheim, diaTribe. Other Relationship; Diabetes UK. Stock/Shareholder; decide Clinical Software GmbH. Advisory Panel; embecta. Speaker's Bureau; embecta, Viatris Inc., Eli Lilly and Company. Advisory Panel; Eli Lilly and Company, Medtronic. Speaker's Bureau; Medtrust. Advisory Panel; Novo Nordisk A/S. Speaker's Bureau; Novo Nordisk A/S. Advisory Panel; PharmaSens, Roche Diabetes Care. Speaker's Bureau; Roche Diabetes Care. Board Member; Sanofi-Aventis Deutschland GmbH. Speaker's Bureau; Sanofi-Aventis Deutschland GmbH, Sanofi, Dexcom, Inc., Viatris Inc. Advisory Panel; Viatris Inc. Speaker's Bureau; Ypsomed AG. Research Support; European Union. Stock/Shareholder; elyte Diagnostics GmbH. Other Relationship; elyte Diagnostics GmbH. Board Member; European Association for the Study of Diabetes. Research Support; European Union Aviation Safety Agency. L. Golden: None. F. Kopp: Other Relationship; Lilly Diabetes, Lilly Diabetes. D.M. Maahs: Advisory Panel; Medtronic. Consultant; Abbott, LifeScan Diabetes Institute, Sanofi, Provention Bio, Inc., Bayer Inc., Kriya Therapeutics, BioSpex. P.M. Jehle: None. O. Ebekozien: Advisory Panel; Sanofi, Medtronic. Research Support; Vertex Pharmaceuticals Incorporated. Speaker's Bureau; Vertex Pharmaceuticals Incorporated. Research Support; Medtronic, Lilly Diabetes, Abbott, Dexcom, Inc. R.W. Holl: None.

Funding
Helmsley Charitable Trust